<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - PRAMIPEXOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>PRAMIPEXOLE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Parkinson's disease, used alone or as an adjunct to co-beneldopa or co-careldopa</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 88 micrograms 3 times a day, increased if tolerated to 350 micrograms 3 times a day, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 180 micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3 mg per day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 260 micrograms once daily, increased to 1.05 mg once daily, dose to be increased by doubling dose every 5&#8211;7 days, then increased in steps of 520 micrograms every 1 week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Restless legs syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 88 micrograms once daily, dose to be taken 2&#8211;3 hours before bedtime, dose to be increased by doubling dose every 4&#8211;7 days, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540 micrograms per day.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>Doses and strengths are stated in terms of pramipexole (base).</p><p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:</p><p>88&#8239;micrograms base &#8801; 125&#8239;micrograms salt;</p><p>180&#8239;micrograms base &#8801; 250&#8239;micrograms salt;</p><p>350&#8239;micrograms base &#8801; 500&#8239;micrograms salt;</p><p>700&#8239;micrograms base &#8801; 1&#8239;mg salt.</p><p>Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for modified-release preparations are as follows:</p><p>260&#8239;micrograms base &#8801; 375&#8239;micrograms salt;</p><p>520&#8239;micrograms base &#8801; 750&#8239;micrograms salt;</p><p>1.05&#8239;mg base &#8801; 1.5&#8239;mg salt;</p><p>1.57&#8239;mg base &#8801; 2.25&#8239;mg salt;</p><p>2.1&#8239;mg base &#8801; 3&#8239;mg salt;</p><p>2.62&#8239;mg base &#8801; 3.75&#8239;mg salt;</p><p>3.15&#8239;mg base &#8801; 4.5&#8239;mg salt.</p>
            </section>
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Use only if potential benefit outweighs risk&#8212;no information available.</p>
            </section>
      </section>


      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>For <i>immediate-release</i> tablets in Parkinson's disease, initially 88&#8239;micrograms twice daily (max. 1.57&#8239;mg daily in 2 divided doses) if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; initially 88&#8239;micrograms once daily (max. 1.1&#8239;mg once daily) if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>. If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR.</p><p>For <i>immediate-release</i> tablets in restless legs syndrome, reduce dose if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>For <i>modified-release</i> tablets, initially 260&#8239;micrograms on alternate days if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, increased to 260&#8239;micrograms once daily after 1 week, further increased if necessary by 260&#8239;micrograms daily at weekly intervals to max. 1.57&#8239;mg daily.</p>
            </section>
        
            <section class="generalInformation">
              <p>For <i>modified-release</i> tablets, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Confusion, constipation, decreased appetite, dizziness, drowsiness, dyskinesia, hallucinations, headache, hyperkinesia, hypotension, nausea, peripheral oedema, postural hypotension, restlessness, sleep disturbances, sudden onset of sleep, visual disturbances, vomiting, weight changes,
              </p>
              <p>
                <strong>uncommon:</strong> Amnesia, binge eating, cardiac failure, compulsive behaviour, delusion, dyspnoea, hiccups, paranoia, pneumonia, pruritus, rash, syncope,
              </p>
              <p>
                <strong>notKnown:</strong> Paradoxical worsening of restless legs syndrome,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="adviceAroundMissedDoses">
                <h3>Sudden onset of sleep</h3>
              <p>Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.</p><p>Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.</p><p>Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.</p>
            </section>
            <section class="adviceAroundMissedDoses">
                <h3>Hypotensive reactions</h3>
              <p>Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Impulse control disorders</h3>
              <p>Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Psychotic disorders
          </li>
          <li>
            risk of visual disorders (ophthalmological testing recommended)
          </li>
          <li>
            severe cardiovascular disease
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Risk of postural hypotension (especially on initiation)&#8212;monitor blood pressure.</p>
            </section>
      </section>



      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of PRAMIPEXOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77137"><a href="../medicinalForm/PHP77137.html" data-target="#PHP77137" data-action="load">Tablet</a></div>
            <div id="PHP77144"><a href="../medicinalForm/PHP77144.html" data-target="#PHP77144" data-action="load">Modified-release tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
